ClinicalTrials.gg
Active, not recruitingNCT07779590Updated Oct 6, 2026

A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

An observational study in Metastatic Castration Sensitive Prostate Cancer (mCSPC), sponsored by Pfizer. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Pfizer · Observational

Updated Oct 6, 2026Now Active, not recruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,700
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Prostatic Neoplasms by Pfizer — 3 open to participants now, 8 under way, 5 of them phase 3. Prostatic Neoplasms · Pfizer.

Started
2026
the only one that year
Observational
7 of 42
none open now
Registered
42nd of 42
by date

Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the only one that started in 2026, is one of 7 observational ones, and was the 42nd registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 42 studies in Prostatic Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Prostatic Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this real-world study of electronic medical records is to look back to compare the time to next treatment after initial treatment with enzalutamide or darolutamide in addition to androgen deprivation therapy (ADT). ADT is a hormone therapy used to stop testosterone from being released or to prevent it from acting on prostate cells. The study includes men with metastatic castration-sensitive prostate cancer (mCSPC). This is a cancer that has spread outside the prostate to other parts of the body, but can still be successfully managed by lowering male hormones like testosterone. The study uses data from the Flatiron's Prostate Cancer Panoramic Database. This data base contains information on prostate cancer patients such as their clinical characteristics, lab, vitals, treatments and outcomes.

This study is seeking participants included in the Flatiron Prostate Cancer Panoramic dataset who:

  • Have a diagnosis of prostate cancer (PC) that has spread to other parts of the body
  • With at least two documented clinic visits on different days in the Flatiron network occurring on or after 01 January 2011
  • Has proof of treatment with enzalutamide or darolutamide in combination with ADT as a first line treatment
  • The treatment with enzalutamide or darolutamide in combination with ADT is no more than 30 days prior to or 6 months after the mCSPC diagnosis date

All participants in this study received at least 1 dose of enzalutamide or darolutamide in combination with ADT. The experiences of the participants receiving the enzalutamide or darolutamide will be looked at.

Participants will take part in this study for at least 6 months. During this time, they will have at least 2 documented clinic visits from 01 January 2011 to 31 March 2026. These visits will be updated if newer information becomes available at the time of the analysis.

03

Conditions studied

  • Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a retrospective cohort study of patients with mCSPC initiating first-line (1L) enzalutamide plus ADT or darolutamide plus ADT without other life-prolonging therapies in the US identified from the Flatiron's Prostate Cancer Panoramic Database. The dataset will include all protocol-required, retrospective patient-level data available for eligible patients from 01 January 2011, through the expected data cutoff date of 31 March 2026, which may be updated if newer data cuts become available at the time of the analysis.

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  1. Patients included in the Flatiron Prostate Cancer Panoramic dataset:

    1. Has an International Classification of Diseases (ICD) diagnosis of PC (ICD-9 185x or ICD-10 C61x)
    2. At least two documented clinic visits on different days in the Flatiron network occurring on or after 01 January 2011
    3. Has evidence of diagnosis of PC with an initial or diagnosis date.
  2. Evidence of mCSPC diagnosis date, as defined below:

    a. The mCSPC diagnosis date is determined using information on the date of metastatic diagnosis and the CSPC status. The data of metastatic diagnosis is the earliest date of the first confirmation of metastatic prostate cancer using the following hierarchy, where available: 1) specimen collection date from the pathology report; 2) Physician reported date of biopsy; 3) Date of the radiology scan that indicated metastatic disease, if it was later confirmed by the physician; 4) Physician reported date of metastatic diagnosis. CSPC status is determined based on the following hierarchical evidence sources: 1) metastatic diagnosis date (if metastatic at initial diagnosis); 2) Explicit clinician documentation of CSPC; 3) Earliest ADT start date; 4) Clinician documented response or PSA decline while on ADT

  3. Has evidence of treatment with enzalutamide or darolutamide in combination with ADT in the 1L mCSPC setting , on or after 01 August 2022.

    Note: The index date is the start of the ARPI in combination with ADT (i.e., the first episode of ARPI treatment, which can occur up to 90 days after initiation of 1L therapy if ADT is initiated before the ARPI).

  4. Index date is no more than 30 days prior to or 6 months after the mCSPC diagnosis date

Patients meeting any of the following criteria will not be included in the study:

  1. Birth sex reported as female or unknown
  2. Age \<18 years at index date
  3. Evidence of receiving a clinical study drug on or prior to index date
  4. Diagnosed with neuroendocrine and/or small cell PC on or prior to index
  5. Diagnosed with additional , excluding nonmelanoma skin cancer, at any time prior to index date
  6. Index date \<6 months prior to data cutoff date
  7. Received multiple ARPIs or ARPI in combination with any drug other than ADT or first-generation anti-androgen treatments prior to and up to 28 days after index date
  8. Evidence of ADT or first-generation anti-androgen treatment between 1 year and 91 days prior to index date
  9. Evidence of an orchiectomy occurring more than 90 days prior to index date
  10. Evidence of CRPC any time prior or up to 90 days after the index date
  11. Evidence of treatments for mCRPC on or prior to index date
  12. Has a Line 0 as defined by Flatiron (LOT) business rules, indicating potentially missing treatment data at the start of mCSPC setting
  13. Received docetaxel prior to and up to 120 days after index date
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,700 participants (estimated)
Patient registry
No

Groups and cohorts

  • darolutamide plus androgen deprivation therapy

    darolutamide plus androgen deprivation therapy

    Drug: darolutamide plus androgen deprivation therapy

  • enzalutamide plus androgen deprivation therapy

    enzalutamide plus androgen deprivation therapy

    Drug: Enzalutamide plus androgen deprivation therapy

Interventions

  • Drugdarolutamide plus androgen deprivation therapy

    Drug page: Darolutamide

    As provided in real world setting

  • DrugEnzalutamide plus androgen deprivation therapy

    Drug page: Enzalutamide

    As provided in real world setting

06

What researchers measure

Primary outcomes

  1. Median Real-world time to next treatment (rwTTNT)

    Time frame: time from index date to the start of the next treatment course (August 1, 2022- March 31, 2026)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 2 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 21, 2026
StartActual
Aug 19, 2026was Sep 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
1 site added — first site in United States
Show site
  • Pfizer · New York, United States
Oct 6, 2026
Start date
Sep 1, 2026→Aug 19, 2026 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in United States
    Show site
    • Pfizer · New York, United States
    Start date Sep 1, 2026→Aug 19, 2026 (now actual)
    + 3 other changes: verification date, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07779590
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Aug 19, 2026
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion